Reyvow

Eli Lilly hit by migraine drug launch slowdown, but rivals jump

As the dust settles around pharma’s second-quarter financial readouts, we check in on how the new and increasingly crowded migraine market is looking.

Ben Adams Aug 5, 2022 11:58am

Lilly finds stigma is one of the top problems for migraine

Jun 22, 2022 7:50am

Reyvow can provide early and lasting migraine relief, Lilly says

Sep 11, 2020 11:14am

With DEA scheduling, Lilly's Reyvow cleared for launch

Jan 31, 2020 11:00am